Most of the fundamental analysts say Gilead Sciences is now undervalued. Now 23 analysts study the company. The recommendations are: 2 times sell, 2 times hold and 19 times buy. The average of the actual target prices for the stock equals 28,57 USD. This is at around 21 percent more than the current price of 72,13 USD. Barclays , Morgan Stanley and Jefferies & Co. recently provided recommendations for the stock.
Gilead Sciences 's market capitalization is based on the number of outstanding shares around 102,57 billion USD.
At 17.14 the stock trades 0,72 percent higher at 72,13 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.